# Journal of Clinica Log In Submit Subscribe An American Society of Clinical Oncology Journal OpenAthens/Shibboleth >>





DEVELOPMENTAL THERAPEUTICS—IMMUNOTHERAPY

A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation.

Mallika Lala, Mengyao Li, Vikram Sinha, Dinesh de Alwis, Elliot Chartash, Lokesh Jain

**Show More** 

**Abstract Disclosures** 

| Δ | bstra | ct |
|---|-------|----|
| _ | usu a | LL |

## 3062

Background: Pembrolizumab is currently approved for use in multiple cancer indications at a dose of either 200 mg or 2 mg/kg Q3W. An alternative extended dosing regimen would provide convenience and flexibility to patients and prescribers. Robust characterization of

# OPTIONS & TOOLS

**Export Citation** 

**Track Citation** 

**Add To Favorites** 

Rights & Permissions



## COMPANION ARTICLES

No companion articles

# ARTICLE CITATION

## DOI:

10.1200/JCO.2018.36.15\_suppl.3062 Journal of Clinical Oncology 36, no. 15\_suppl (May 20, 2018) 3062-3062.

Published online June 01, 2018.

and E-R relationships for efficacy and safety allow the use of model-based approaches to support alternative dosing regimens. **Methods:** The dose for a Q6W schedule was selected by matching exposures with the approved Q3W (200 mg and 2 mg/kg) regimens; efficacy and safety are bridged based on E-R assessments. Exposures were simulated using the established population PK model of pembrolizumab that adequately described PK across multiple tumor types. Regimens are compared on - A) Exposure metrics at steady state: AUCss or timeaveraged concentration (Cavg,ss) and trough concentrations (Cmin,ss); B) Predicted clinical endpoints (e.g., objective response rate) in patients with multiple approved tumor types. Safety at the Q6W schedule is bridged by ensuring predicted peak concentrations at steady state (Cmax,ss) are below those at the maximum clinically administered and well-tolerated dose of 10 mg/kg Q2W. **Results:** The 400 mg Q6W dosing regimen had similar predicted exposures (Cavg,ss or AUCss, geometric mean (GM) ~1% higher) compared to those achieved at 200 mg Q3W. Less than 1% subjects had Cmin,ss lower than that for 200 mg Q3W. The GM of predicted Cmax,ss for 400 mg Q6W was ~65% lower than for 10 mg/kg Q2W. Given the similar exposures and established E-R relationships for pembrolizumab over a 5-fold range of clinically tested doses, the clinical outcomes achieved with 400 mg Q6W are predicted to be similar as with 200 mg Q3W across tumor types. Conclusions: A 400 mg Q6W dosing regimen of

pembrolizumab pharmacokinetics (PK)

# WHAT'S POPULAR

## **Most Read**

## **Most Cited**

Management of
Immune-Related
Adverse Events in
Patients Treated
With Immune
Checkpoint Inhibitor
Therapy: American
Society of Clinical
Oncology Clinical
Practice Guideline
Brahmer et al.

Outpatient
Management of
Fever and
Neutropenia in
Adults Treated for
Malignancy:
American Society of
Clinical Oncology
and Infectious
Diseases Society of
America Clinical
Practice Guideline
Update
Taplitz et al.

## American Society of

**Antiemetics:** 

Clinical Oncology
Clinical Practice
Guideline Update
Hesketh et al.

Minimal Residual
Disease Assessed by
Multiparameter Flow
Cytometry in
Multiple Myeloma:
Impact on Outcome
in the Medical
Research Council
Myeloma IX Study
Rawstron et al.

pembrolizumab leads to exposures that are similar to the approved 200 mg Q3W dosing regimen. Based on the robust understanding of pembrolizumab clinical pharmacology, including well-established E-R profiles, such a less frequent dosing regimen is expected to produce similar efficacy, safety, and benefit-risk profile in all clinical treatment settings where 200 mg Q3W pembrolizumab is currently approved.

Comparison of an Oral Factor Xa
Inhibitor With Low Molecular Weight
Heparin in Patients
With Cancer With
Venous
Thromboembolism:
Results of a
Randomized Trial
(SELECT-D)
Young et al.



## **QUICK LINKS**

## Content

Newest Articles Archive Meeting Abstracts

## Journal Information

About
Editorial Roster
Contact Us
Permissions

#### Resources

Authors Reviewers Subscribers Institutions Advertisers

Submit Your Manuscript

Subscribe to this Journal



## **ASCO FAMILY OF SITES**

## **Journals**

Journal of Clinical
Oncology
Journal of Oncology
Practice
Journal of Global
Oncology
JCO Clinical Cancer
Informatics
JCO Precision
Oncology

### **Publications**

ASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post JOP DAIS

## **Education**

ASCO University ASCO Meetings Cancer.Net

**Other Sites** 

ASCO.org
ASCO Author
Services
ASCO Career Center
CancerLinQ
Conquer Cancer
Foundation
TAPUR Study











American Society of Clinical Oncology 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology

Terms of Use | Privacy Policy | Cookies